Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

Fig. 5

The effect of NVP-Bez235 and lenalidomide in cell cycle. a Cell lines were treated with components for 72 h, collected and fixed by 70 % ethanol for 24 h. Cell cycle assay was assessed with cytometry and Modfit LT. b The Bar graph illustrated the proportion of G0/G1 phase, S phase, G2/M phase of cell lines treated as mentioned above. Era bars indicated the standard deviation (n = 3). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.005 compared with control group. c Western blot for cell lysis collected after treated with single agent or combination agents for 72 h

Back to article page